Overview

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belongs to the family of growth hormone-releasing peptides (GHRPs) but displays a significantly cleaner pharmacological profile than earlier generations. In laboratory models, it selectively targets the pituitary gland to release growth hormone in a manner that closely mimics natural physiological pulses, making it a premier tool for studying somatotropic signaling without disrupting general endocrine homeostasis.

Click to view CoA Information

Key Research Effects & Mechanisms

• Highly Selective Somatotroph Stimulation: Unlike other secretagogues (such as GHRP-2 or GHRP-6), Ipamorelin does not cause an increase in the secretion of stress hormones like cortisol or lactogenic hormones like prolactin. This precise selectivity allows researchers to isolate and study pure growth hormone release pathways.

• Adipose Tissue Lipolysis & Weight Management: By increasing the systemic availability of native growth hormone, Ipamorelin triggers downstream signaling that accelerates the breakdown of lipids in adipose tissue. Research models track its efficacy in optimizing body composition by favoring fat oxidation over storage.

• Lean Tissue Preservation & Protein Synthesis: Exposure to Ipamorelin correlates with enhanced nitrogen retention and upregulated protein synthesis in skeletal muscle tissue. This makes it a primary subject for investigations involving muscle-wasting models and lean tissue preservation.

• Bone Mineral Density Support: Long-term cellular models suggest that growth hormone secretagogues influence osteoblast activity. Ipamorelin is actively researched for its potential role in boosting bone mineral content and structural skeletal density.

Disclaimer: This product is for research purposes only. It is not intended for direct human consumption.